Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$1.67 USD
-0.02 (-1.18%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $1.66 -0.01 (-0.60%) 7:58 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
Checkpoint Therapeutics, Inc. [CKPT]
Reports for Purchase
Showing records 1 - 20 ( 46 total )
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Non-Fundamental CRL a Minor Unfortunate Delay; 2024 Approval Still In the Cards
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Three Near-Term PDUFAs Should Drive Significant Long-Time Coming Value
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pre-PDUFA Feather in the Cap; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosi Continues to Deliver; Longer Term Data Show Durability of Clinical Benefit; PDUFA Janury 3, 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosi Profile Should Drive Commercialization Success; Shares Disconnect Persists; Target Adjusted to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In FDA''s Capable Accepting Hands; Cosi PDUFA Set for January 3, 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosi BLA Filed; We Project Favorable Label For This Disruptive Asset; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Time Is Now to Get Cozy With Cosi as First Endgame Nears; Split-Adjusted Target to $76
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Whole Package; Green Light for Locally Advanced cSCC to Be Included in Cosibelimab BLA Submission in YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosimelibab Also Benefits Locally Advanced CSCC Following Positive Metastatic Pivotal Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pictures Speak Volumes for Cosi Pivotal Data at ASCO; More Data This Month and BLA Not Too Far Off
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cosibelimab Clears Key Regulatory Hurdle in Europe; BLA Submission on Track for YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 5.00
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Focus is on Upcoming Cosibelimab BLA and Ongoing BD Activities; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Cosibelimab BLA Submission by YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pazdur Grumblings Still Place Checkpoint''s Assets Favorably in the Global Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It''s a Beautiful Day in the Neighborhood; Cosi Nails It; Target Upped to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Second Pivotal Launches; We''re Excited for First Pivotal Data Imminently; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 5.00
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Cosibelimab Top-Line Data Imminent; BLA Submission Within Spitting Distance
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Checkpoint Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key 2021 Universe Catalysts to Focus On as Market Turbulence Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00